Grifols
- Country
- 🇪🇸Spain
- Ownership
- Subsidiary, Public
- Established
- 1940-01-01
- Employees
- 23.7K
- Market Cap
- $6.8B
- Website
- http://www.grifols.com
- Introduction
Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products an...
Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)
- Conditions
- Interventions
- First Posted Date
- 2017-11-24
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 28
- Registration Number
- NCT03351933
- Locations
- 🇺🇸
Vince & Associates Clinical Research, Inc., Overland Park, Kansas, United States
Alphanate in Immune Tolerance Induction Therapy
- First Posted Date
- 2017-03-29
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 2
- Registration Number
- NCT03095287
- Locations
- 🇺🇸
Newark Beth Israel Medical Center & Children's Hospital of New Jersey, Newark, New Jersey, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
🇮🇳Lokmanya Tilak Municipal Medical College & General Hospital, Mumbai, Maharashtra, India
Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 12
- Registration Number
- NCT02872142
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 4
- Registration Number
- NCT02870348
- Locations
- 🇯🇵
Hiroskai University Hospital, Aomori, Japan
🇯🇵Hokkaido University Hospital, Hokkaido, Japan
🇯🇵Juntendo University Hospital, Tokyo, Japan
Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 4
- Registration Number
- NCT02870309
- Locations
- 🇯🇵
Juntendo University Hospital, Tokyo, Japan
🇯🇵Hokkaido University Hospital, Sapporo, Japan
Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 61
- Registration Number
- NCT02806986
- Locations
- 🇫🇷
CHU de Montpellier, Montpellier, France
🇪🇸Hospital Universitario Vall d'Hebron, Barcelona, Spain
🇨🇿University Hospital, Hradec Kralove, Czechia
Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency
- Conditions
- Interventions
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 290
- Registration Number
- NCT02796937
- Locations
- 🇺🇸
Accellacare, Wilmington, North Carolina, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
🇦🇺Royal Adelaide Hospital, Adelaide, Australia
Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency
- Conditions
- Interventions
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2019-10-04
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 53
- Registration Number
- NCT02604810
- Locations
- 🇺🇸
Allergy Associates of The Palm Beaches, PA, North Palm Beach, Florida, United States
🇺🇸University of South Florida, Saint Petersburg, Florida, United States
🇨🇦CHU Sainte-Justine, Montreal, Quebec, Canada
A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
- First Posted Date
- 2015-06-17
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 62
- Registration Number
- NCT02473952
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸University of Florida Health Science Center, Jacksonville, Florida, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
- First Posted Date
- 2015-06-17
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 60
- Registration Number
- NCT02473965
- Locations
- 🇺🇸
University of California-Irvine, Orange, California, United States
🇺🇸University of Florida at Shands Jacksonville, Jacksonville, Florida, United States
🇺🇸Columbia University Medical Center, New York, New York, United States